Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359801 · ClinicalTrials.gov registry record · Phase 4
Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,976
- Enrollment target
NCT00359801 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 1,976 participants.
The verdict
NCT00359801, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,976 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term pulmonary and cardiovascular safety of Exubera in routine clinical practice.
Interventions
- DRUG Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,976 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359801
The ClinicalTrials.gov registry entry for NCT00359801 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,976 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care is the first listed.
NCT00359801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359801 about?
NCT00359801 is a clinical study titled "Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety". The purpose of this study is to evaluate the long-term pulmonary and cardiovascular safety of Exubera in routine clinical practice.
What is the current status of trial NCT00359801?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,976 participants. The study started on 2006-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00359801?
The interventions under investigation include: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care (DRUG).
Who is sponsoring clinical trial NCT00359801?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.